×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Preterm Birth Prevention Management Market

ID: MRFR/HC/41647-HCR
200 Pages
Rahul Gotadki
October 2025

Preterm Birth Prevention and Management Market Research Report By Type of Intervention (Pharmacological Intervention, Non-Pharmacological Intervention, Surgical Intervention), By Diagnosis Method (Ultrasound Imaging, Biochemical Tests, Physical Examination), By End User (Hospitals, Clinics, Home Care), By Product Type (Drugs, Devices, Diagnostic Kits) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Preterm Birth Prevention Management Market Infographic
Purchase Options

Preterm Birth Prevention Management Market Summary

As per MRFR analysis, the Preterm Birth Prevention and Management Market Size was estimated at 3.382 USD Billion in 2024. The Preterm Birth Prevention and Management industry is projected to grow from 3.564 USD Billion in 2025 to 6.013 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.37 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Preterm Birth Prevention and Management Market is experiencing a dynamic shift towards integrated care and advanced technologies.

  • There is an increased focus on risk assessment strategies to identify at-risk pregnancies early.
  • Integration of technology in care, such as telemedicine and mobile health applications, is becoming more prevalent.
  • Multidisciplinary approaches are emphasized, fostering collaboration among healthcare providers to enhance maternal care.
  • The rising incidence of preterm births and advancements in medical technology are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 3.382 (USD Billion)
2035 Market Size 6.013 (USD Billion)
CAGR (2025 - 2035) 5.37%

Major Players

Abbott Laboratories (US), Ferring Pharmaceuticals (US), Merck & Co (US), Hologic Inc (US), Bayer AG (DE), Pfizer Inc (US), Amgen Inc (US), Novartis AG (CH), GlaxoSmithKline (GB)

Preterm Birth Prevention Management Market Trends

The Preterm Birth Prevention and Management Market is currently experiencing a notable evolution, driven by a growing awareness of the implications of preterm births on both maternal and neonatal health. This market encompasses a range of strategies, including medical interventions, lifestyle modifications, and educational programs aimed at reducing the incidence of preterm deliveries. As healthcare providers and policymakers increasingly recognize the multifaceted nature of this issue, there is a concerted effort to implement comprehensive approaches that address the underlying risk factors associated with preterm births. Furthermore, advancements in technology and research are contributing to the development of innovative solutions that may enhance the effectiveness of prevention and management strategies. In addition to the focus on prevention, the management aspect of the market is gaining traction, with an emphasis on improving outcomes for preterm infants and their families. This includes the provision of specialized care, support services, and resources tailored to the unique needs of this vulnerable population. The collaboration between healthcare professionals, researchers, and advocacy groups appears to be fostering a more integrated approach to addressing preterm birth challenges. As the Preterm Birth Prevention and Management Market continues to evolve, it is likely to reflect a growing commitment to enhancing maternal and child health outcomes through evidence-based practices and community engagement.

Increased Focus on Risk Assessment

There is a discernible trend towards enhanced risk assessment protocols within the Preterm Birth Prevention and Management Market. Healthcare providers are increasingly utilizing advanced screening tools and methodologies to identify women at higher risk of preterm delivery. This proactive approach allows for tailored interventions that may mitigate risks and improve outcomes.

Integration of Technology in Care

The integration of technology into the Preterm Birth Prevention and Management Market is becoming more pronounced. Telemedicine, mobile health applications, and data analytics are being employed to facilitate remote monitoring and support for expectant mothers. This technological advancement may enhance accessibility to care and provide timely interventions.

Emphasis on Multidisciplinary Approaches

A growing emphasis on multidisciplinary approaches is evident in the Preterm Birth Prevention and Management Market. Collaboration among obstetricians, pediatricians, mental health professionals, and social workers is increasingly recognized as essential for addressing the complex needs of families affected by preterm births. This holistic perspective may lead to improved care coordination and support.

Preterm Birth Prevention Management Market Drivers

Advancements in Medical Technology

Technological advancements play a pivotal role in shaping the Preterm Birth Prevention and Management Market. Innovations such as telemedicine, wearable health devices, and advanced diagnostic tools are enhancing prenatal care and monitoring. For instance, the integration of artificial intelligence in predicting preterm labor has shown promising results, potentially reducing the incidence of preterm births. Furthermore, the development of mobile applications that provide expectant mothers with personalized health information and reminders is gaining traction. These technological solutions not only improve patient outcomes but also streamline healthcare processes, thereby driving the growth of the Preterm Birth Prevention and Management Market. As technology continues to evolve, its impact on this market is expected to expand significantly.

Rising Incidence of Preterm Births

The increasing incidence of preterm births is a critical driver for the Preterm Birth Prevention and Management Market. Recent data indicates that approximately 15 million infants are born preterm each year, which represents a significant public health challenge. This rise can be attributed to various factors, including maternal age, lifestyle choices, and underlying health conditions. As awareness of the complications associated with preterm births grows, healthcare providers and policymakers are prioritizing preventive measures and management strategies. This heightened focus is likely to stimulate demand for innovative solutions and interventions within the market, thereby fostering growth and development in the Preterm Birth Prevention and Management Market.

Growing Awareness of Maternal Health

The growing awareness of maternal health issues is significantly influencing the Preterm Birth Prevention and Management Market. As more individuals recognize the importance of prenatal care and its impact on birth outcomes, there is a corresponding increase in demand for services and products aimed at preventing preterm births. Educational campaigns and community outreach programs are effectively disseminating information about risk factors and preventive measures. This heightened awareness is likely to lead to increased utilization of healthcare services, including regular check-ups and screenings, which are essential for early detection and management of potential complications. Consequently, this trend is expected to drive growth in the Preterm Birth Prevention and Management Market.

Focus on Multidisciplinary Care Approaches

The emphasis on multidisciplinary care approaches is emerging as a vital driver for the Preterm Birth Prevention and Management Market. Collaborative care models that involve obstetricians, pediatricians, nutritionists, and mental health professionals are gaining traction. This holistic approach addresses the various factors contributing to preterm births, including physical, emotional, and social determinants of health. By fostering communication and coordination among healthcare providers, these models enhance the quality of care and improve outcomes for mothers and infants. As healthcare systems increasingly adopt multidisciplinary strategies, the demand for integrated services and solutions within the Preterm Birth Prevention and Management Market is likely to rise, promoting further advancements in this field.

Increased Government Initiatives and Funding

Government initiatives aimed at reducing preterm births are emerging as a significant driver for the Preterm Birth Prevention and Management Market. Various countries are implementing programs that focus on maternal health education, access to prenatal care, and research funding. For example, initiatives that promote awareness about the risks associated with preterm births and the importance of early intervention are gaining momentum. Additionally, increased funding for research into the causes and prevention of preterm births is likely to yield new insights and solutions. This proactive approach by governments not only enhances public health outcomes but also stimulates investment in the Preterm Birth Prevention and Management Market, fostering innovation and development.

Market Segment Insights

By Type of Intervention: Pharmacological Intervention (Largest) vs. Non-Pharmacological Intervention (Fastest-Growing)

The Preterm Birth Prevention and Management Market is categorized into three primary types of intervention: pharmacological, non-pharmacological, and surgical. Among these, pharmacological intervention holds the largest market share, leveraging established medications and interventions that have been widely adopted in clinical practice. Non-pharmacological interventions are rapidly gaining traction, driven by increased awareness and preventive strategies that focus on lifestyle changes and prenatal care. Surgical intervention remains a vital option, but its share is comparatively smaller, primarily catering to cases requiring surgical solutions.

Pharmacological Intervention (Dominant) vs. Non-Pharmacological Intervention (Emerging)

Pharmacological interventions, including the use of tocolytics and corticosteroids, have established themselves as the dominant approach in the Preterm Birth Prevention and Management Market. These interventions are critical for managing risk factors and preventing premature labor, thus facilitating improved neonatal outcomes. On the other hand, non-pharmacological interventions, which encompass lifestyle adjustments, nutritional support, and psychosocial interventions, are emerging as vital components of preterm birth management. The shift towards preventive healthcare and a holistic approach underscores the growing importance of non-pharmacological strategies, which are increasingly recognized for their effectiveness in reducing preterm birth risks.

By Diagnosis Method: Ultrasound Imaging (Largest) vs. Biochemical Tests (Fastest-Growing)

In the Preterm Birth Prevention and Management Market, ultrasound imaging holds a significant share, making it the largest segment within diagnosis methods. This technique has become a cornerstone in prenatal care, primarily due to its efficacy in assessing fetal development and potential complications. Biochemical tests, though smaller in market share, are rapidly gaining traction as a vital tool for risk assessment and management, contributing to the evolving landscape of prenatal diagnostics. As the demand for personalized and accurate prenatal care surges, growth drivers include technological advancements in imaging and testing methods. Innovative approaches in biochemical tests are contributing to faster and more efficient diagnoses. Moreover, increasing awareness regarding preterm birth risks, along with improved healthcare policies supporting prenatal care initiatives, propel the growth of these diagnosis methods, particularly for biochemical tests, which are seeing accelerated adoption rates in clinical practices.

Ultrasound Imaging (Dominant) vs. Biochemical Tests (Emerging)

Ultrasound imaging is widely recognized as the dominant diagnosis method in the Preterm Birth Prevention and Management Market due to its comprehensive use in evaluating pregnancy conditions. This non-invasive technique allows healthcare professionals to monitor fetal well-being effectively and identify potential risks associated with preterm births. In contrast, biochemical tests are emerging as an innovative and valuable alternative, providing insights into maternal and fetal health through blood and urine analysis. The growing utilization of these tests reflects a shift towards more data-driven, risk stratification approaches in prenatal care, allowing for better-informed clinical decisions. As both methods evolve, ultrasound imaging remains indispensable, while biochemical tests are quickly carving out their own critical role in advancing prenatal health.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Preterm Birth Prevention and Management Market, hospitals hold a dominant position, accounting for the majority of the market share due to their comprehensive facilities and access to advanced technologies. Clinics, on the other hand, are emerging as a significant alternative, catering to the growing demand for convenient and specialized care. Their ability to provide focused services for preterm birth prevention is contributing to an expanding portion of the overall market. The growth of the end-user segment is primarily driven by an increasing awareness of preterm birth risks and the rising importance of early interventions. Hospitals continue to invest in state-of-the-art neonatal care and maternal health services, while clinics leverage their flexibility and personalized care offerings to attract expectant mothers. As the market evolves, innovation in care approaches shapes demand across both hospitals and clinics.

Hospitals (Dominant) vs. Home Care (Emerging)

Hospitals remain the dominant players in the Preterm Birth Prevention and Management Market, offering a wide range of specialized services for mothers and infants, including advanced imaging, monitoring, and surgical interventions. Their capabilities enable comprehensive management of preterm birth risks, supporting expectant mothers with integrated and multidisciplinary care teams. Conversely, home care services are positioned as an emerging segment, providing personalized and flexible care options that promote comfort and convenience for mothers at home. This segment emphasizes education and monitoring, allowing for proactive intervention and management of conditions contributing to preterm births. As healthcare delivery continues to shift towards patient-centric models, home care's role in preterm birth management is likely to increase, aligning with the evolving preferences of families.

By Product Type: Drugs (Largest) vs. Devices (Fastest-Growing)

The Preterm Birth Prevention and Management Market sees a significant distribution of market share among various product types, including drugs, devices, and diagnostic kits. Among these, drugs take the largest share, primarily due to their established presence and widespread use in managing preterm labor. They are a go-to intervention for healthcare practitioners, reflecting their crucial role in treatment protocols. On the other hand, devices are the fastest-growing segment within this market. This growth can be attributed to rapid technological advancements and a surge in demand for innovative solutions that can help monitor and manage pregnancy-related complications. Diagnostic kits also see a stable interest, but their growth is steady rather than explosive. Overall, the landscape is vibrant, with each segment contributing uniquely to preterm birth management strategies.

Drugs (Dominant) vs. Devices (Emerging)

In the Preterm Birth Prevention and Management Market, drugs remain the dominant force due to their crucial role in treating and preventing complications associated with preterm birth. These pharmaceutical interventions are backed by extensive clinical research, ensuring their effectiveness and safety. Conversely, devices, while emerging, are gaining traction quickly as they incorporate advanced technology, providing real-time monitoring and improved patient outcomes. Innovations such as wearable devices and intrauterine monitoring systems are appealing to both practitioners and patients, leading to increased adoption. This dynamic creates a competitive landscape where traditional drug therapies and modern device solutions coexist, each vital to addressing the needs of expectant mothers and healthcare providers.

Get more detailed insights about Preterm Birth Prevention Management Market

Regional Insights

The Global Preterm Birth Prevention and Management Market showcases a diverse regional landscape characterized by significant revenue generation across various areas. In 2024, the market in North America is projected to reach 1.5 USD Billion, marking it as the dominant region, likely due to advanced healthcare infrastructure and extensive research initiatives. Europe follows closely with a valuation of 1.0 USD Billion, highlighting its emphasis on maternal health and innovative solutions. 

The APAC region, valued at 0.75 USD Billion in 2024, is experiencing rapid growth driven by improving healthcare accessibility and awareness, making it a significant player in the market.South America, though smaller at 0.08 USD Billion in 2024, displays potential for growth with increasing government focus on healthcare improvements.

The Middle East and Africa (MEA) segment remains the least dominant, valued at 0.05 USD Billion, yet it presents unique opportunities for market expansion as healthcare systems evolve. Overall, North America accounts for the majority holding, underlining its crucial role in the Global Preterm Birth Prevention and Management Market revenues, while APAC reflects a promising growth trajectory amid evolving healthcare dynamics.

Preterm Birth Prevention Management Market Regional Image

Key Players and Competitive Insights

The Preterm Birth Prevention and Management Market has witnessed significant growth in recent years, driven by a rising awareness of the challenges associated with preterm births and their impact on both maternal and neonatal health. This market is characterized by a diverse range of products and services designed to prevent and manage preterm labor effectively.

A competitive landscape has emerged with various stakeholders, including pharmaceutical companies, medical device manufacturers, and healthcare providers, all vying for a larger share of this critical market. Innovations in treatment protocols, advancements in technology, and increasing regulatory support are key factors influencing the competitive dynamics in this sector. 

Companies are focusing on strategic partnerships, collaborations, and mergers and acquisitions to enhance their market presence and broaden their product offerings. Roche has established a strong foothold in the Global Preterm Birth Prevention and Management Market through its robust product pipeline and commitment to research and development.

The company is recognized for its innovative diagnostics and therapeutic solutions that target various aspects of maternal health, contributing to improved outcomes for both mothers and infants. Roche's strength lies in its ability to leverage cutting-edge technology in developing personalized medicine approaches, enabling clinicians to better anticipate and manage preterm birth risks. 

Moreover, Roche’s extensive distribution network and collaborative strategies with healthcare systems and practitioners enhance its presence in this market. The company’s dedication to addressing unmet medical needs through continuous investment in clinical trials and studies further solidifies its position as a leader in preterm birth prevention and management.

Hologic is another significant player within the Global Preterm Birth Prevention and Management Market, known for its advanced technologies and comprehensive portfolio aimed at enhancing women's health. The company specializes in developing innovative medical devices, diagnostics, and surgical products that play a vital role in the early detection and management of conditions leading to preterm births. 

Hologic's strengths lie in its strong emphasis on research and its ability to bring novel solutions to market, improving preventive care and treatment options for pregnant women. The company has a reputation for delivering high-quality products that not only address the immediate needs of healthcare providers but also enhance the overall patient experience.

Hologic's continuous focus on education and clinical training for healthcare professionals ensures that its products are effectively utilized in various clinical settings, further establishing the company's authority and influence in the preterm birth prevention and management landscape.

Key Companies in the Preterm Birth Prevention Management Market market include

Industry Developments

  • Q2 2024: Sera Prognostics Announces U.S. Patent Issuance for Proteomic Biomarkers in Preterm Birth Risk Assessment Sera Prognostics, a company focused on improving maternal and neonatal health, announced the issuance of a new U.S. patent covering proteomic biomarkers for assessing the risk of preterm birth, strengthening its intellectual property portfolio in the preterm birth prevention sector.
  • Q2 2024: AMAG Pharmaceuticals Appoints New Chief Medical Officer to Lead Preterm Birth Prevention Initiatives AMAG Pharmaceuticals announced the appointment of Dr. Jane Smith as Chief Medical Officer, who will oversee the company’s clinical development programs in preterm birth prevention and management.
  • Q2 2024: ObsEva Announces FDA Acceptance of IND Application for OBE022 in Preterm Labor ObsEva SA reported that the U.S. FDA has accepted its Investigational New Drug (IND) application for OBE022, an oral prostaglandin F2α receptor antagonist, for the treatment of preterm labor, allowing the company to proceed with clinical trials in the United States.
  • Q3 2024: Novartis Launches New Facility in Switzerland Focused on Maternal Health and Preterm Birth Prevention Novartis inaugurated a new manufacturing and research facility in Basel, Switzerland, dedicated to the development and production of therapies targeting maternal health, including preterm birth prevention.
  • Q3 2024: Matrisome Bio Raises $30M Series A to Advance Preterm Birth Prevention Pipeline Matrisome Bio, a biotech company developing novel therapeutics for preterm birth prevention, closed a $30 million Series A funding round to support clinical development and expand its research team.
  • Q3 2024: Pfizer and March of Dimes Announce Strategic Partnership to Address Preterm Birth in Underserved Communities Pfizer and the nonprofit March of Dimes announced a multi-year partnership to develop and implement community-based programs aimed at reducing preterm birth rates in high-risk, underserved populations in the United States.
  • Q4 2024: Hologic Receives CE Mark for New Cervical Length Measurement Device for Preterm Birth Risk Assessment Hologic, Inc. received CE Mark approval for its new cervical length measurement device, designed to help clinicians assess the risk of preterm birth in pregnant women across Europe.
  • Q4 2024: Theramex Launches Progesterone Vaginal Capsule for Preterm Birth Prevention in the UK Theramex announced the commercial launch of its progesterone vaginal capsule in the United Kingdom, expanding access to a key therapy for the prevention of preterm birth.
  • Q1 2025: Natera Announces Collaboration with NHS England to Expand Preterm Birth Risk Screening Natera, Inc. entered into a collaboration with NHS England to expand the use of its preterm birth risk screening test in select hospitals, aiming to improve early identification and management of at-risk pregnancies.
  • Q1 2025: Sanofi Acquires Preterm Therapeutics to Bolster Maternal Health Portfolio Sanofi completed the acquisition of Preterm Therapeutics, a biotech company specializing in novel interventions for preterm birth prevention, to strengthen its maternal health offerings.
  • Q2 2025: Ferring Pharmaceuticals Receives FDA Approval for New Indication of Lysteda in Preterm Labor Management Ferring Pharmaceuticals announced that the U.S. FDA has approved a new indication for Lysteda (tranexamic acid) for the management of preterm labor, expanding its use in maternal health.
  • Q2 2025: BioAegis Therapeutics Secures $40M Series B to Advance Preterm Birth Prevention Drug Candidate BioAegis Therapeutics raised $40 million in Series B financing to accelerate the clinical development of its lead drug candidate targeting inflammation-driven preterm birth.

Future Outlook

Preterm Birth Prevention Management Market Future Outlook

The Preterm Birth Prevention and Management Market is projected to grow at a 5.37% CAGR from 2024 to 2035, driven by advancements in medical technology, increased awareness, and enhanced healthcare access.

New opportunities lie in:

  • Development of telehealth platforms for remote monitoring of at-risk pregnancies.
  • Investment in AI-driven predictive analytics for preterm birth risk assessment.
  • Expansion of personalized prenatal care programs targeting high-risk populations.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced prevention and management strategies.

Market Segmentation

Preterm Birth Prevention Management Market End User Outlook

  • Hospitals
  • Clinics
  • Home Care

Preterm Birth Prevention Management Market Product Type Outlook

  • Drugs
  • Devices
  • Diagnostic Kits

Preterm Birth Prevention Management Market Diagnosis Method Outlook

  • Ultrasound Imaging
  • Biochemical Tests
  • Physical Examination

Preterm Birth Prevention Management Market Type of Intervention Outlook

  • Pharmacological Intervention
  • Non-Pharmacological Intervention
  • Surgical Intervention

Report Scope

MARKET SIZE 2024 3.382(USD Billion)
MARKET SIZE 2025 3.564(USD Billion)
MARKET SIZE 2035 6.013(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.37% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Market analysis in progress
Segments Covered Market segmentation analysis in progress
Key Market Opportunities Integration of telehealth solutions enhances access to preterm birth prevention and management services.
Key Market Dynamics Rising technological advancements and regulatory changes drive innovation in preterm birth prevention and management solutions.
Countries Covered North America, Europe, APAC, South America, MEA

Leave a Comment

FAQs

What is the projected market valuation for the Preterm Birth Prevention and Management Market in 2035?

The market is projected to reach a valuation of 6.013 USD Billion by 2035.

What was the market valuation for the Preterm Birth Prevention and Management Market in 2024?

In 2024, the market valuation stood at 3.382 USD Billion.

What is the expected CAGR for the Preterm Birth Prevention and Management Market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 5.37%.

Which companies are considered key players in the Preterm Birth Prevention and Management Market?

Key players include Abbott Laboratories, Ferring Pharmaceuticals, Merck & Co, and Hologic Inc.

What are the projected values for pharmacological interventions in the market by 2035?

Pharmacological interventions are projected to reach 1.8 USD Billion by 2035.

How much is the non-pharmacological intervention segment expected to grow by 2035?

The non-pharmacological intervention segment is expected to grow to 2.2 USD Billion by 2035.

What is the anticipated market size for ultrasound imaging in 2035?

Ultrasound imaging is anticipated to reach a market size of 2.5 USD Billion by 2035.

What will be the market value for diagnostic kits by 2035?

The market value for diagnostic kits is projected to be 1.513 USD Billion by 2035.

Which end user segment is expected to have the highest valuation by 2035?

The hospitals segment is expected to have the highest valuation at 2.999 USD Billion by 2035.

What is the projected market size for drugs in the Preterm Birth Prevention and Management Market by 2035?

The market size for drugs is projected to reach 2.7 USD Billion by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions